<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0163523</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-13257</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Colorectal cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject><subj-group><subject>Surgical oncology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Clinical medicine</subject><subj-group><subject>Clinical oncology</subject><subj-group><subject>Surgical oncology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Clinical oncology</subject><subj-group><subject>Surgical oncology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Elevated Platelet to Lymphocyte Ratio Is Associated with Poor Survival Outcomes in Patients with Colorectal Cancer</article-title>
<alt-title alt-title-type="running-head">PLR for Prognosis in CRC</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Gu</surname>
<given-names>Xiaobin</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Gao</surname>
<given-names>Xian-Shu</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Qin</surname>
<given-names>Shangbin</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Xiaoying</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Qi</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ma</surname>
<given-names>Mingwei</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yu</surname>
<given-names>Hao</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Shaoqian</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhou</surname>
<given-names>Dong</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>Wen</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Xiong</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Tangshan People’s Hospital, Hebei, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Chalmers</surname>
<given-names>Jeffrey</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>The Ohio State University, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple">
<list-item><p><bold>Conceptualization:</bold> XBG XSG.</p></list-item>
<list-item><p><bold>Data curation:</bold> XBG XSG.</p></list-item>
<list-item><p><bold>Formal analysis:</bold> XBG XSG SBQ XYL.</p></list-item>
<list-item><p><bold>Funding acquisition:</bold> XBG XSG.</p></list-item>
<list-item><p><bold>Investigation:</bold> HY SQS WW WX.</p></list-item>
<list-item><p><bold>Methodology:</bold> SBQ XYL XQ.</p></list-item>
<list-item><p><bold>Project administration:</bold> XSG WX.</p></list-item>
<list-item><p><bold>Resources:</bold> XSG WW MWM DZ.</p></list-item>
<list-item><p><bold>Software:</bold> XBG MWM HY.</p></list-item>
<list-item><p><bold>Supervision:</bold> XSG XQ.</p></list-item>
<list-item><p><bold>Validation:</bold> SQS DZ WW WX.</p></list-item>
<list-item><p><bold>Visualization:</bold> XBG XSG.</p></list-item>
<list-item><p><bold>Writing – original draft:</bold> XBG XSG.</p></list-item>
<list-item><p><bold>Writing – review &amp; editing:</bold> XSG MWM.</p></list-item></list></p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">doctorgaoxs@126.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>9</issue>
<elocation-id>e0163523</elocation-id>
<history>
<date date-type="received">
<day>1</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>9</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Gu et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0163523"/>
<abstract>
<p>Platelet to lymphocyte ratio (PLR) is a parameter reflecting inflammatory responses in patients with cancer. Several studies have investigated the prognostic value of PLR in patients with colorectal cancer (CRC); however, the results are controversial. Thus, we carried out a meta-analysis to evaluate the association between PLR and CRC prognostication. Relevant articles were retrieved through PubMed, Embase, and Web of Science, and pooled hazard ratio (HR) and 95% confidence interval (CI) were computed by using STATA V.12.0. Both the random-effects model and fixed-effects model were utilized. A total of 13 studies (14 cohorts) with 8,601 patients were included in the meta-analysis. Pooled HRs and 95% CIs demonstrated that increased PLR predicted poor overall survival (OS) (HR = 1.81, 95%CI:1.42–2.31, p&lt;0.001; I<sup>2</sup> = 65%, P<sub>h</sub> = 0.002), disease-free survival (DFS) (HR = 1.84, 95%CI:1.22–2.76, p = 0.003; I<sup>2</sup> = 78.3%, P<sub>h</sub>&lt;0.001) and recurrence-free survival (RFS) (HR = 1.84, 95%CI:1.41–2.41, p&lt;0.001; I<sup>2</sup> = 0, P<sub>h</sub> = 0.686), although this was not the case for cancer-specific survival (CSS) (HR = 1.75, 95%CI:0.59–5.17, p = 0.309; I<sup>2</sup> = 66.2%, P<sub>h</sub> = 0.085) or time to recurrence (TTR) (HR = 1.21 95%CI:0.62–2.36, p = 0.573;I<sup>2</sup> = 58.4%, P<sub>h</sub> = 0.121). Subgroup analysis showed that PLR enhanced the prognostic value for OS in Caucasian patients, in small sample studies and for metastatic disease; however, this was not the case with rectal cancer. Furthermore, elevated PLR predicted reduced DFS in Caucasians and not in Asians. In conclusion, our meta-analysis showed that high PLR was a significant biomarker for poor OS, DFS, and RFS in patients with CRC; however, it had no association with CSS or TTR.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Gu</surname>
<given-names>Xiaobin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Gao</surname>
<given-names>Xian-Shu</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Qin</surname>
<given-names>Shangbin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Li</surname>
<given-names>Xiaoying</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Qi</surname>
<given-names>Xin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Ma</surname>
<given-names>Mingwei</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Yu</surname>
<given-names>Hao</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award008">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Sun</surname>
<given-names>Shaoqian</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award009">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhou</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award010">
<funding-source>
<institution>Clinical Features Research of Capital</institution>
</funding-source>
<award-id>Z141107002514160</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Wang</surname>
<given-names>Wen</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by a grant from the Clinical Features Research of Capital (No. Z141107002514160).</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<page-count count="14"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Colorectal cancer (CRC) is ranked as the third most commonly diagnosed cancer type and the fourth most frequent cause of cancer-related deaths around the world[<xref ref-type="bibr" rid="pone.0163523.ref001">1</xref>]. In the United States, CRC accounts for 8% of new cancer cases and 8% of cancer deaths in men and women[<xref ref-type="bibr" rid="pone.0163523.ref002">2</xref>]. Significant progress has been achieved in the past two decades to improve the clinical outcomes of CRC, including the approval of several therapeutic agents for chemotherapy and targeted therapy [<xref ref-type="bibr" rid="pone.0163523.ref003">3</xref>]. Despite this, 24%-41% of patients die within 5 years following a surgical resection with curative intent, and 56%-78% of patients die within 2 years after palliative resection [<xref ref-type="bibr" rid="pone.0163523.ref004">4</xref>]. Therefore, it is necessary to identify novel and readily available prognostic biomarkers for risk stratification and to predict treatment efficiency in CRC.</p>
<p>Inflammation has been indicated to serve a pivotal role in cancer development[<xref ref-type="bibr" rid="pone.0163523.ref005">5</xref>]. Inflammatory responses can facilitate tumor progression in different stages, including initiation, proliferation, angiogenesis, invasion, and metastasis [<xref ref-type="bibr" rid="pone.0163523.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0163523.ref007">7</xref>]. In recent years, blood based inflammatory parameters including neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), have attracted extensive attention and have been studied in a wide spectrum of diseases[<xref ref-type="bibr" rid="pone.0163523.ref008">8</xref>–<xref ref-type="bibr" rid="pone.0163523.ref010">10</xref>]. This is because these indexes of systemic inflammation are easy to measure and provide useful information for prognosis [<xref ref-type="bibr" rid="pone.0163523.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0163523.ref012">12</xref>]. PLR is calculated as the platelet count divided by the lymphocyte count. In the process of tumor angiogenesis, proangiogenic mediators could promote the release of platelets[<xref ref-type="bibr" rid="pone.0163523.ref013">13</xref>]. In addition, antiplatelet agents have been shown to inhibit the growth ability of cancer cells by down-regulating matrix metalloproteinase-9 [<xref ref-type="bibr" rid="pone.0163523.ref014">14</xref>]. Therefore, platelets could reflect the invasive potential of cancer cells to some extent. Lymphocytes, by contrast, are involved in cancer immune surveillance [<xref ref-type="bibr" rid="pone.0163523.ref015">15</xref>]. Lymphocytes also participate in tumor defense by inducing cytotoxic cell death and suppressing the proliferation of tumor cells as well as their maturation [<xref ref-type="bibr" rid="pone.0163523.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0163523.ref016">16</xref>]. Therefore, the index combining platelets and lymphocytes, PLR, could provide a relatively objective and reliable measurement of the protumor and antitumor effects in patients. Compared with platelets, lymphocytes have a greater involvement in systemic inflammatory responses in patients with cancer and are more easily to be influenced. Therefore, the changes in lymphocyte counts have a more profound influence on PLR. High PLR has been shown to be a potential prognostic indicator in a variety of solid tumors, such as gastric cancer[<xref ref-type="bibr" rid="pone.0163523.ref017">17</xref>], non-small-cell lung cancer[<xref ref-type="bibr" rid="pone.0163523.ref018">18</xref>], breast cancer[<xref ref-type="bibr" rid="pone.0163523.ref019">19</xref>] and hepatocellular carcinoma[<xref ref-type="bibr" rid="pone.0163523.ref020">20</xref>]. In addition, a series of studies were designed to investigate the prognostic value of PLR in colorectal cancer [<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>]; however, the data in these studies presented inconsistent and inconclusive results. Therefore, a comprehensive analysis combining the controversial data is required.</p>
<p>The aim of this study was to provide a systematic and comprehensive evaluation of the prognostic value of PLR in CRC by meta-analysis. We combined results from 13 studies and assessed the prognosis role of PLR for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), cancer-specific survival (CSS), and time to recurrence (TTR) in CRC.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec003">
<title>Literature search</title>
<p>This meta-analysis was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PRISMA checklist was shown in <xref ref-type="supplementary-material" rid="pone.0163523.s001">S1 PRISMA Checklist</xref>. A thorough literature search was performed in the databases of PubMed, Embase, and Web of Science. The latest search was updated on March, 2016. The following terms were used: “PLR or platelet to lymphocyte ratio or platelet-lymphocyte ratio” and “colon cancer or rectal cancer or colorectal cancer or colorectal neoplasms”. References from relevant articles were also examined for possible inclusions.</p>
</sec>
<sec id="sec004">
<title>Selection criteria</title>
<p>The inclusion criteria were as follows: 1. the diagnosis of CRC was pathologically established; 2. the value of PLR was measured by blood based approaches prior to treatment; 3. information between PLR and clinical outcomes including OS, DFS, RFS, CSS and/or TTR was provided or sufficient data was provided for the estimation of hazard ratio (HR) and 95% confidence interval (CI); 4. a cut-off value to define high PLR was provided; 5. for overlapping studies, the most recent one was selected; 6. the study was published in English. The exclusion criteria were as follows: 1. letters, reviews, meeting abstracts, case reports or nonhuman studies; 2. insufficient data to estimate HRs and 95% CIs; 3. overlapping or duplicate studies.</p>
</sec>
<sec id="sec005">
<title>Data extraction</title>
<p>Two investigators (XB,G and XS,G) independently extracted the following information from the included studies: first author, publication year, country, study period, sample size, tumor stage, tumor location, PLR cut-off value, treatment methods, and survival analysis. Regarding treatment methods, in the case that all patients received any combination of surgical resection, chemotherapy and radiotherapy treatment, the treatment method was identified as “mixed”. In the event that all of the patients received surgical resection while only a number of them received chemotherapy or radiotherapy, the treatment method was labeled as “surgery”. Any disagreement between the two investigators was settled by discussion.</p>
</sec>
<sec id="sec006">
<title>Statistical analysis</title>
<p>HRs and 95% CIs were selected to assess the association between PLR and prognosis in CRC. Cochran’s Q test[<xref ref-type="bibr" rid="pone.0163523.ref028">28</xref>] and the Higgins I<sup>2</sup> statistic[<xref ref-type="bibr" rid="pone.0163523.ref029">29</xref>] were used to estimate heterogeneity. I<sup>2</sup>&gt;50% or P<sub>h</sub>&lt;0.1 indicated significant heterogeneity. Both the random-effects model (DerSimonian Laird method)[<xref ref-type="bibr" rid="pone.0163523.ref030">30</xref>] and fixed-effects model (Mantel Haenszel method)[<xref ref-type="bibr" rid="pone.0163523.ref031">31</xref>] were employed to calculate combined HRs and 95% CIs. In the event that significant heterogeneity was found, the random-effects model was selected to explain the results, while, the fixed-effects model was used. Subgroup analysis stratified by clinical and pathological factors was performed to investigate and interpret heterogeneity between different studies. Publication bias was evaluated by Begg’s funnel plot[<xref ref-type="bibr" rid="pone.0163523.ref032">32</xref>] and Egger’s test[<xref ref-type="bibr" rid="pone.0163523.ref033">33</xref>]. All statistical analyses were performed using STATA V.12.0 (Stata Corp, College Station, TX). P&lt;0.05 was considered as statistically significant.</p>
</sec>
</sec>
<sec id="sec007" sec-type="results">
<title>Results</title>
<sec id="sec008">
<title>Literature selection and characteristics of included studies</title>
<p>The initial literature search identified 210 records from the databases of PubMed, Embase, and Web of Science, and reference lists. Subsequent to an evaluation of these records, 181 records were excluded because they were reviews, irrelevant studies, meeting abstracts, duplicate records or animal studies. Therefore, 29 full-text articles were examined for eligibility. Sixteen records were further excluded after analysis of the full-text because they failed to provide key information, did not present a PLR cut-off value, had been published as a letter or were duplicate articles from the same research group. As in Baranyai’s study[<xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>], the investigators recruited 336 patients with CRC and 118 patients with metastatic CRC (mCRC). The CRC group and mCRC group were independent cohorts and were analyzed separately, and thus, we named the CRC cohort ‘Baranyai1’ and the mCRC cohort ‘Baranyai2’. Finally, 13 studies (14 cohorts)[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>–<xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>] were included in the meta-analysis. The literature selection procedures are shown in <xref ref-type="fig" rid="pone.0163523.g001">Fig 1</xref>. All of the included studies had a retrospective study design, and were published between 2012 and 2016. Four studies[<xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>–<xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>] were conducted in China, three [<xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>–<xref ref-type="bibr" rid="pone.0163523.ref036">36</xref>] were performed in Japan, two [<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>] were carried out in UK, one study was performed in Korea [<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>], one was from Hungary [<xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>], one was conducted in Austria [<xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>] and one was performed in Canada [<xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>]. The total sample size of the 13 studies (14 cohorts) was 8,601. The main characteristics of included studies were depicted in <xref ref-type="table" rid="pone.0163523.t001">Table 1</xref>.</p>
<fig id="pone.0163523.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163523.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow diagram of literature selection.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0163523.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163523.t001</object-id>
<label>Table 1</label> <caption><title>Main characteristics of included studies.</title></caption>
<alternatives>
<graphic id="pone.0163523.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Year</th>
<th align="left">Country</th>
<th align="left">Ethnicity</th>
<th align="left">Study period</th>
<th align="left">No. of patients</th>
<th align="left">Gender (M/F)</th>
<th align="left">Tumor stage</th>
<th align="left">Tumor location</th>
<th align="left">Treatment</th>
<th align="left">Cut-off</th>
<th align="left">Follow-up (month)</th>
<th align="left">Survival analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Carruthers</td>
<td align="left">2012</td>
<td align="left">UK</td>
<td align="left">Caucasian</td>
<td align="left">2000–2005</td>
<td align="left">115</td>
<td align="left">75/40</td>
<td align="left">Ⅰ-Ⅲ</td>
<td align="left">Rectum</td>
<td align="left">Mixed</td>
<td align="left">160</td>
<td align="left">37.1</td>
<td align="left">OS,DFS,TTR</td>
</tr>
<tr>
<td align="left">Son</td>
<td align="left">2013</td>
<td align="left">Korea</td>
<td align="left">Asian</td>
<td align="left">2005–2007</td>
<td align="left">624</td>
<td align="left">368/256</td>
<td align="left">Ⅰ-Ⅲ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">300</td>
<td align="left">42(1–66)</td>
<td align="left">OS,DFS</td>
</tr>
<tr>
<td align="left">Baranyai1</td>
<td align="left">2014</td>
<td align="left">Hungary</td>
<td align="left">Caucasian</td>
<td align="left">2001–2011</td>
<td align="left">336</td>
<td align="left">180/156</td>
<td align="left">Ⅰ-Ⅳ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">300</td>
<td align="left">36.1</td>
<td align="left">OS,DFS</td>
</tr>
<tr>
<td align="left">Baranyai2</td>
<td align="left">2014</td>
<td align="left">Hungary</td>
<td align="left">Caucasian</td>
<td align="left">2001–2011</td>
<td align="left">118</td>
<td align="left">80/38</td>
<td align="left">Ⅳ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">300</td>
<td align="left">36.1</td>
<td align="left">OS</td>
</tr>
<tr>
<td align="left">Neofytou</td>
<td align="left">2014</td>
<td align="left">UK</td>
<td align="left">Caucasian</td>
<td align="left">2005–2012</td>
<td align="left">140</td>
<td align="left">88/52</td>
<td align="left">Ⅳ</td>
<td align="left">Colorectum</td>
<td align="left">Mixed</td>
<td align="left">150</td>
<td align="left">33(1–103)</td>
<td align="left">OS,DFS</td>
</tr>
<tr>
<td align="left">Szkandera</td>
<td align="left">2014</td>
<td align="left">Austria</td>
<td align="left">Caucasian</td>
<td align="left">1996–2011</td>
<td align="left">372</td>
<td align="left">217/155</td>
<td align="left">Ⅱ-Ⅲ</td>
<td align="left">Colon</td>
<td align="left">Surgery</td>
<td align="left">176,225<xref ref-type="table-fn" rid="t001fn002"><sup>a</sup></xref></td>
<td align="left">68(1–190)</td>
<td align="left">OS,TTR</td>
</tr>
<tr>
<td align="left">Ying</td>
<td align="left">2014</td>
<td align="left">China</td>
<td align="left">Asian</td>
<td align="left">2005–2010</td>
<td align="left">205</td>
<td align="left">144/61</td>
<td align="left">Ⅰ-Ⅲ</td>
<td align="left">Colorectum</td>
<td align="left">Surgrey</td>
<td align="left">176</td>
<td align="left">To Dec,2013</td>
<td align="left">OS,RFS,CSS</td>
</tr>
<tr>
<td align="left">Choi</td>
<td align="left">2015</td>
<td align="left">Canada</td>
<td align="left">Caucasian</td>
<td align="left">2004–2012</td>
<td align="left">549</td>
<td align="left">296/253</td>
<td align="left">Ⅰ-Ⅲ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">295</td>
<td align="left">NA</td>
<td align="left">OS,RFS</td>
</tr>
<tr>
<td align="left">Mori</td>
<td align="left">2015</td>
<td align="left">Japan</td>
<td align="left">Asian</td>
<td align="left">2007–2011</td>
<td align="left">157</td>
<td align="left">90/67</td>
<td align="left">Ⅰ-Ⅲ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">150</td>
<td align="left">20.5(0.2–62.4)</td>
<td align="left">DFS</td>
</tr>
<tr>
<td align="left">Ozawa</td>
<td align="left">2015</td>
<td align="left">Japan</td>
<td align="left">Asian</td>
<td align="left">2000–2010</td>
<td align="left">234</td>
<td align="left">142/92</td>
<td align="left">Ⅱ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">254</td>
<td align="left">64(1–173)</td>
<td align="left">OS,DFS,CSS</td>
</tr>
<tr>
<td align="left">Toiyama</td>
<td align="left">2015</td>
<td align="left">Japan</td>
<td align="left">Asian</td>
<td align="left">2001–2012</td>
<td align="left">89</td>
<td align="left">66/23</td>
<td align="left">Ⅰ-Ⅲ</td>
<td align="left">Rectum</td>
<td align="left">Mixed</td>
<td align="left">150</td>
<td align="left">NA</td>
<td align="left">OS,RFS</td>
</tr>
<tr>
<td align="left">Li</td>
<td align="left">2016</td>
<td align="left">China</td>
<td align="left">Asian</td>
<td align="left">2007–2014</td>
<td align="left">5,336</td>
<td align="left">3,167/2,169</td>
<td align="left">Ⅰ-Ⅲ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">219</td>
<td align="left">55.2</td>
<td align="left">OS,DFS</td>
</tr>
<tr>
<td align="left">Li</td>
<td align="left">2016</td>
<td align="left">China</td>
<td align="left">Asian</td>
<td align="left">2003–2012</td>
<td align="left">110</td>
<td align="left">58/52</td>
<td align="left">Ⅳ</td>
<td align="left">Colon</td>
<td align="left">Mixed</td>
<td align="left">162</td>
<td align="left">0.9–122</td>
<td align="left">OS</td>
</tr>
<tr>
<td align="left">Zou</td>
<td align="left">2016</td>
<td align="left">China</td>
<td align="left">Asian</td>
<td align="left">2006–2012</td>
<td align="left">216</td>
<td align="left">137/79</td>
<td align="left">Ⅰ-Ⅳ</td>
<td align="left">Colorectum</td>
<td align="left">Surgery</td>
<td align="left">246.36</td>
<td align="left">To Jul,2013</td>
<td align="left">OS</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>OS: overall survival; DFS: disease-free survival; TTR: time to recurrence; CSS: cancer-specific survival; RFS: recurrence-free survival; NA: not available</p></fn>
<fn id="t001fn002"><p><sup>a</sup>:176 for TTR, 225 for OS.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec009">
<title>PLR and prognosis for OS</title>
<p>A total of 12 studies (13 cohorts)[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>–<xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>] with 8,444 patients were used to investigate the relationship between PLR and OS in CRC. The pooled HR and 95%CI were HR = 1.81, 95%CI:1.42–2.31, p&lt;0.001 in the random-effects model, with heterogeneity (I<sup>2</sup> = 65%, P<sub>h</sub> = 0.002)(<xref ref-type="fig" rid="pone.0163523.g002">Fig 2</xref>, <xref ref-type="table" rid="pone.0163523.t002">Table 2</xref>). Subgroup analysis stratified by ethnicity, sample size, tumor location, metastasis status, and treatment demonstrated that PLR had an enhanced prognostic value in Caucasian patients (HR = 1.95, 95%CI: 1.35–2.8, p&lt;0.001; I<sup>2</sup> = 59%, P<sub>h</sub> = 0.032), in small sample studies (n&lt;300): HR = 1.94, 95%CI: 1.57–2.4, p&lt;0.001 with moderate heterogeneity (I<sup>2</sup> = 23.7%, Ph = 0.24) and for those with metastatic disease (HR = 1.98, 95%CI: 1.1–3.55, p = 0.022; I<sup>2</sup> = 57.1%, P<sub>h</sub> = 0.097). High PLR also predicted poor OS in CRC (HR = 1.94, 95%CI: 1.4–2.68, p&lt;0.001; I<sup>2</sup> = 70.8%, P<sub>h</sub> = 0.001); however, the difference was not significant in rectal cancer (HR = 1.25, 95%CI: 0.75–2.14, p = 0.404; I<sup>2</sup> = 29.3%, P<sub>h</sub> = 0.234).</p>
<fig id="pone.0163523.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163523.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plot of HR for the association between PLR and OS stratified by tumor location in CRC.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.g002" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0163523.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163523.t002</object-id>
<label>Table 2</label> <caption><title>Summary of the meta-analysis results.</title></caption>
<alternatives>
<graphic id="pone.0163523.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Analysis</th>
<th align="left" rowspan="2">No. of studies</th>
<th align="left" rowspan="2">Percent (%)</th>
<th align="left" rowspan="2">References</th>
<th align="left" rowspan="2">No. of patients</th>
<th align="left" colspan="2">Random-effects model</th>
<th align="left" colspan="2">Fixed-effects model</th>
<th align="left" colspan="2">Heterogeneity</th>
</tr>
<tr>
<th align="left">HR(95%CI)</th>
<th align="left">p</th>
<th align="left">HR(95%CI)</th>
<th align="left">p</th>
<th align="left">I<sup>2</sup>(%)</th>
<th align="left">P<sub>h</sub></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">OS</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Overall</td>
<td align="left">13</td>
<td align="left">100</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>–<xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>]</td>
<td align="left">8,444</td>
<td align="left">1.81(1.42–2.31)</td>
<td align="left">&lt;0.001</td>
<td align="left">1.65(1.45–1.89)</td>
<td align="left">&lt;0.001</td>
<td align="left">61.5</td>
<td align="left">0.002</td>
</tr>
<tr>
<td align="left">Subgroup1: ethnicity</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Caucasian</td>
<td align="left">6</td>
<td align="left">46.15</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>–<xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>]</td>
<td align="left">1,630</td>
<td align="left">1.95(1.35–2.8)</td>
<td align="left">&lt;0.001</td>
<td align="left">2.04(1.62–2.56)</td>
<td align="left">&lt;0.001</td>
<td align="left">59</td>
<td align="left">0.032</td>
</tr>
<tr>
<td align="left">Asian</td>
<td align="left">7</td>
<td align="left">53.85</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>–<xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>]</td>
<td align="left">6,814</td>
<td align="left">1.69(1.23–2.32)</td>
<td align="left">0.001</td>
<td align="left">1.48(1.26–1.75)</td>
<td align="left">&lt;0.001</td>
<td align="left">56.9</td>
<td align="left">0.03</td>
</tr>
<tr>
<td align="left">Subgroup2: sample size</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">&gt;300</td>
<td align="left">5</td>
<td align="left">38.46</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>]</td>
<td align="left">7,217</td>
<td align="left">1.81(1.15–2.86)</td>
<td align="left">0.011</td>
<td align="left">1.48(1.25–1.76)</td>
<td align="left">&lt;0.001</td>
<td align="left">78</td>
<td align="left">0.001</td>
</tr>
<tr>
<td align="left">&lt;300</td>
<td align="left">8</td>
<td align="left">61.54</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref036">36</xref>, <xref ref-type="bibr" rid="pone.0163523.ref038">38</xref>, <xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>]</td>
<td align="left">1,227</td>
<td align="left">1.9(1.48–2.44)</td>
<td align="left">&lt;0.001</td>
<td align="left">1.94(1.57–2.4)</td>
<td align="left">&lt;0.001</td>
<td align="left">23.7</td>
<td align="left">0.24</td>
</tr>
<tr>
<td align="left">Subgroup3: tumor location</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Rectum</td>
<td align="left">2</td>
<td align="left">15.38</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref036">36</xref>]</td>
<td align="left">204</td>
<td align="left">1.18(0.59–2.36)</td>
<td align="left">0.636</td>
<td align="left">1.25(0.75–2.14)</td>
<td align="left">0.404</td>
<td align="left">29.3</td>
<td align="left">0.234</td>
</tr>
<tr>
<td align="left">Colon</td>
<td align="left">2</td>
<td align="left">15.38</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0163523.ref038">38</xref>]</td>
<td align="left">482</td>
<td align="left">1.82(1.25–2.65)</td>
<td align="left">0.002</td>
<td align="left">1.82(1.26–2.61)</td>
<td align="left">0.001</td>
<td align="left">6.3</td>
<td align="left">0.301</td>
</tr>
<tr>
<td align="left">Colorectum</td>
<td align="left">9</td>
<td align="left">69.24</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>–<xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>, <xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>]</td>
<td align="left">7,758</td>
<td align="left">1.94(1.4–2.68)</td>
<td align="left">&lt;0.001</td>
<td align="left">1.66(1.43–1.93)</td>
<td align="left">&lt;0.001</td>
<td align="left">70.8</td>
<td align="left">0.001</td>
</tr>
<tr>
<td align="left">Subgroup4: metastasis</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Localized</td>
<td align="left">10</td>
<td align="left">76.92</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>–<xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>–<xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>, <xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>]</td>
<td align="left">8,076</td>
<td align="left">1.76(1.34–2.23)</td>
<td align="left">&lt;0.001</td>
<td align="left">1.59(1.38–1.83)</td>
<td align="left">&lt;0.001</td>
<td align="left">63</td>
<td align="left">0.004</td>
</tr>
<tr>
<td align="left">Metastatic</td>
<td align="left">3</td>
<td align="left">23.08</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref038">38</xref>]</td>
<td align="left">368</td>
<td align="left">1.98(1.1–3.55)</td>
<td align="left">0.022</td>
<td align="left">2.14(1.48–3.09)</td>
<td align="left">&lt;0.001</td>
<td align="left">57.1</td>
<td align="left">0.097</td>
</tr>
<tr>
<td align="left">Subgroup5: treatment</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Mixed</td>
<td align="left">4</td>
<td align="left">30.77</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref036">36</xref>, <xref ref-type="bibr" rid="pone.0163523.ref038">38</xref>]</td>
<td align="left">454</td>
<td align="left">1.85(1.15–2.98)</td>
<td align="left">0.012</td>
<td align="left">1.97(1.43–2.71)</td>
<td align="left">&lt;0.001</td>
<td align="left">50.8</td>
<td align="left">0.107</td>
</tr>
<tr>
<td align="left">Surgery</td>
<td align="left">9</td>
<td align="left">69.23</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>–<xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>, <xref ref-type="bibr" rid="pone.0163523.ref039">39</xref>]</td>
<td align="left">7,990</td>
<td align="left">1.8(1.34–2.41)</td>
<td align="left">&lt;0.001</td>
<td align="left">1.59(1.38–1.84)</td>
<td align="left">&lt;0.001</td>
<td align="left">66.2</td>
<td align="left">0.003</td>
</tr>
<tr>
<td align="left">DFS</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Overall</td>
<td align="left">7</td>
<td align="left">100</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>]</td>
<td align="left">6,942</td>
<td align="left">1.84(1.22–2.76)</td>
<td align="left">0.003</td>
<td align="left">1.28(1.13–1.46)</td>
<td align="left">&lt;0.001</td>
<td align="left">78.3</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">Subgroup1: ethnicity</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Caucasian</td>
<td align="left">3</td>
<td align="left">42.86</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>]</td>
<td align="left">591</td>
<td align="left">1.93(1.12–3.34)</td>
<td align="left">0.018</td>
<td align="left">1.92(1.45–2.53)</td>
<td align="left">&lt;0.001</td>
<td align="left">72.9</td>
<td align="left">0.025</td>
</tr>
<tr>
<td align="left">Asian</td>
<td align="left">4</td>
<td align="left">57.14</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>]</td>
<td align="left">6,351</td>
<td align="left">1.78(0.97–3.26)</td>
<td align="left">0.064</td>
<td align="left">1.15(0.99–1.33)</td>
<td align="left">0.067</td>
<td align="left">69.7</td>
<td align="left">0.019</td>
</tr>
<tr>
<td align="left">Subgroup2: sample size</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">&gt;300</td>
<td align="left">3</td>
<td align="left">42.86</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>]</td>
<td align="left">6,296</td>
<td align="left">1.84(0.76–4.44)</td>
<td align="left">0.177</td>
<td align="left">1.18(1.02–1.36)</td>
<td align="left">0.028</td>
<td align="left">88.5</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">&lt;300</td>
<td align="left">4</td>
<td align="left">57.14</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>]</td>
<td align="left">646</td>
<td align="left">1.8(1.28–2.54)</td>
<td align="left">0.001</td>
<td align="left">1.77(1.34–2.35)</td>
<td align="left">&lt;0.001</td>
<td align="left">24</td>
<td align="left">0.267</td>
</tr>
<tr>
<td align="left">Subgroup3: tumor location</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Rectum</td>
<td align="left">1</td>
<td align="left">14.29</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>]</td>
<td align="left">115</td>
<td align="left">1.2(0.69–2.08)</td>
<td align="left">0.515</td>
<td align="left">1.2(0.69–2.08)</td>
<td align="left">0.515</td>
<td align="left">-</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left">Colorectum</td>
<td align="left">6</td>
<td align="left">85.71</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>–<xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>]</td>
<td align="left">6,827</td>
<td align="left">2.01(1.24–3.25)</td>
<td align="left">0.005</td>
<td align="left">1.29(1.13–1.27)</td>
<td align="left">&lt;0.001</td>
<td align="left">81.8</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">Subgroup4: treatment</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Mixed</td>
<td align="left">2</td>
<td align="left">28.57</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>]</td>
<td align="left">255</td>
<td align="left">1.53(1.05–2.23)</td>
<td align="left">0.027</td>
<td align="left">1.55(1.12–2.15)</td>
<td align="left">0.008</td>
<td align="left">22.1</td>
<td align="left">0.257</td>
</tr>
<tr>
<td align="left">Surgery</td>
<td align="left">5</td>
<td align="left">71.43</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0163523.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>]</td>
<td align="left">6,687</td>
<td align="left">2.11(1.11–4.01)</td>
<td align="left">0.023</td>
<td align="left">1.24(1.08–1.43)</td>
<td align="left">0.003</td>
<td align="left">83.9</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">RFS</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Overall</td>
<td align="left">3</td>
<td align="left">100</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref036">36</xref>]</td>
<td align="left">843</td>
<td align="left">1.84(1.41–2.41)</td>
<td align="left">&lt;0.001</td>
<td align="left">1.84(1.41–2.41)</td>
<td align="left">&lt;0.001</td>
<td align="left">0</td>
<td align="left">0.686</td>
</tr>
<tr>
<td align="left">CSS</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Overall</td>
<td align="left">2</td>
<td align="left">100</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>]</td>
<td align="left">439</td>
<td align="left">1.75(0.59–5.17)</td>
<td align="left">0.309</td>
<td align="left">1.3(0.87–1.96)</td>
<td align="left">0.202</td>
<td align="left">66.2</td>
<td align="left">0.085</td>
</tr>
<tr>
<td align="left">TTR</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Overall</td>
<td align="left">2</td>
<td align="left">100</td>
<td align="left">[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>]</td>
<td align="left">487</td>
<td align="left">1.21(0.62–2.36)</td>
<td align="left">0.573</td>
<td align="left">1.33(0.91–1.96)</td>
<td align="left">0.145</td>
<td align="left">58.4</td>
<td align="left">0.121</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec010">
<title>PLR and prognosis for DFS</title>
<p>Seven studies[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0163523.ref037">37</xref>] involving a total of 6,942 subjects provided the data of PLR for DFS prognosis. The overall HR and 95% CI were HR = 1.84, 95%CI:1.22–2.76, p = 0.003, although with heterogeneity (I<sup>2</sup> = 78.3%, P<sub>h</sub>&lt;0.001)(<xref ref-type="fig" rid="pone.0163523.g003">Fig 3</xref>, <xref ref-type="table" rid="pone.0163523.t002">Table 2</xref>). Stratified analysis suggested that elevated PLR predicted reduced DFS in Caucasian patients (HR = 1.93, 95%CI: 1.12–3.34, p = 0.018; I<sup>2</sup> = 72.9%, P<sub>h</sub> = 0.025); however, the result was not statistically significant for Asian patients (HR = 1.78, 95%CI: 0.97–3.26, p = 0.064; I<sup>2</sup> = 69.7%, P<sub>h</sub> = 0.019) (<xref ref-type="table" rid="pone.0163523.t002">Table 2</xref>). High PLR was also associated with poorer DFS in patients treated with surgery (HR = 2.11, 95%CI: 1.11–4.01, p = 0.023; I<sup>2</sup> = 83.9%, P<sub>h</sub>&lt;0.001).</p>
<fig id="pone.0163523.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163523.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Forest plot of HR for the association between PLR and DFS stratified by ethnicity in CRC.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec011">
<title>PLR and prognosis for RFS, CSS, and TTR</title>
<p>Three studies [<xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0163523.ref036">36</xref>] involving a total of 843 patients included data for PLR in RFS. The combined HR and 95%CI were HR = 1.84, 95%CI:1.41–2.41, p&lt;0.001, with fine homogeneity (I<sup>2</sup> = 0,P<sub>h</sub> = 0.686). Pooled data from two studies [<xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref035">35</xref>] showed that PLR had no statistically significant association with poor CSS in the random-effects model or in the fixed effects model (<xref ref-type="table" rid="pone.0163523.t002">Table 2</xref>). High PLR was also not able to predict poor TTR statistically, according to the pooled HRs and 95% CIs from two articles [<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>].</p>
</sec>
<sec id="sec012">
<title>Publication bias</title>
<p>Begg’s test and Egger’s test were employed to examine the publication bias in the meta-analysis. As shown in <xref ref-type="table" rid="pone.0163523.t003">Table 3</xref> and <xref ref-type="fig" rid="pone.0163523.g004">Fig 4</xref>, the results indicated that there was no significant publication bias present for OS, DFS, RFS, CSS and TTR analyses.</p>
<fig id="pone.0163523.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163523.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Publication bias assessed by Begg’s test and Egger’s test.</title>
<p>(A) Begg’s test for OS; (B) Egger’s test for OS; (C) Begg’s test for DFS; (D) Egger’s test for DFS; (E) Begg’s test for RFS; (F) Egger’s test for RFS.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.g004" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0163523.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163523.t003</object-id>
<label>Table 3</label> <caption><title>Publication bias examined by Begg’s test and Egger’s test in meta-analysis.</title></caption>
<alternatives>
<graphic id="pone.0163523.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="left">No. of studies</th>
<th align="left">Begg’s p</th>
<th align="left">Egger’s p</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">OS</td>
<td align="left">13</td>
<td align="left">0.36</td>
<td align="left">0.3</td>
</tr>
<tr>
<td align="left">DFS</td>
<td align="left">7</td>
<td align="left">0.881</td>
<td align="left">0.064</td>
</tr>
<tr>
<td align="left">RFS</td>
<td align="left">3</td>
<td align="left">0.291</td>
<td align="left">0.319</td>
</tr>
<tr>
<td align="left">CSS</td>
<td align="left">2</td>
<td align="left">1</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left">TTR</td>
<td align="left">2</td>
<td align="left">1</td>
<td align="left">-</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>In recent years, a series of studies have investigated prognostic role of PLR for CRC, selecting different events, including OS, DFS, RFS, CSS, and TTR as the end-point events. However, these studies have reported conflicting results. While a number of studies[<xref ref-type="bibr" rid="pone.0163523.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0163523.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0163523.ref038">38</xref>] suggested PLR to be an effective prognostic biomarker for CRC, other studies[<xref ref-type="bibr" rid="pone.0163523.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0163523.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0163523.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0163523.ref036">36</xref>] reported negative results with respect to the prognostication for PLR. In the present study, by using the meta-analysis analytic approach, we demonstrated that PLR predicted poor OS in CRC, especially in Caucasian patients, for metastatic disease and for CRC; however, it was not able to predict poor OS for rectal cancer. Moreover, a high PLR was correlated with shorter DFS in the overall analysis and had a more significant prognostic value in patients who had received surgery. Furthermore, PLR was also associated with poor RFS, without heterogeneity. However, there was no association between PLR and CSS and TTR in CRC. To the best of our knowledge, this is the first meta-analysis comprehensively exploring the prognostic value of PLR in CRC.</p>
<p>Growing evidence has shown that there is an association between inflammation and tumorigenesis [<xref ref-type="bibr" rid="pone.0163523.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0163523.ref016">16</xref>]. Recently, tumor-promoting inflammation was established as an emerging hallmark of cancer [<xref ref-type="bibr" rid="pone.0163523.ref007">7</xref>]. Persistence of the inflammatory responses in the tumor microenvironment results in the proliferation of tumor cells, in addition to their metastasis and angiogenesis. Markers of systemic inflammation such as NLR, PLR and C-reactive protein can provide implications for prognosis in CRC [<xref ref-type="bibr" rid="pone.0163523.ref040">40</xref>, <xref ref-type="bibr" rid="pone.0163523.ref041">41</xref>]. By contrast, prior studies have demonstrated that platelets are involved in the process of tumor angiogenesis [<xref ref-type="bibr" rid="pone.0163523.ref042">42</xref>]. Thrombocytosis is a frequent phenomenon in malignant tumors. A recent study showed that platelet-derived signals were required to guide tumor cells to construct “early metastatic niches”[<xref ref-type="bibr" rid="pone.0163523.ref043">43</xref>]. Furthermore, lymphocytes exert an indispensable role in the antitumor activity of the host by inducing tumor cell apoptosis and by inhibiting tumor metastasis [<xref ref-type="bibr" rid="pone.0163523.ref044">44</xref>]. Moreover, they are able to recognize tumor antigens and exert effects in antitumor responses through mediating antibody-dependent cytotoxicity. Previous studies have reported that an elevation in platelet count is correlated with poor prognosis in colorectal cancer [<xref ref-type="bibr" rid="pone.0163523.ref045">45</xref>, <xref ref-type="bibr" rid="pone.0163523.ref046">46</xref>]. Current evidence also shows that low tumor-infiltrating lymphocytes are significantly associated with lower 5-year OS and DFS rates in CRC[<xref ref-type="bibr" rid="pone.0163523.ref047">47</xref>]. Based on the biological rationality, the combination of platelets and lymphocytes could be more extensively altered in CRC patients than each one of them. Furthermore, when platelet counts increased and/or lymphocyte counts decreased, the ratio altered more significantly. Moreover, PLR, as a value that combines the platelet and lymphocyte counts, is a more stable indicator of the antitumor status of patients with cancer. In addition, PLR is not difficult to test and involves no added costs, making it suitable to apply in routine clinical settings. Therefore, PLR is a useful and valuable prognostic index.</p>
<p>PLR has been widely explored as a prognostic indicator in various types of cancers. Several meta-analyses have shown that PLR is associated with poor prognosis in patients with non-small-cell lung cancer [<xref ref-type="bibr" rid="pone.0163523.ref048">48</xref>], which was in accordance with our study. Previous studies have also investigated PLR for its predictive role in various solid tumors using meta-analysis [<xref ref-type="bibr" rid="pone.0163523.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0163523.ref049">49</xref>, <xref ref-type="bibr" rid="pone.0163523.ref050">50</xref>]. These studies showed that PLR predicted poor prognosis in CRC, in addition to a variety of other tumors. However, the patients with CRC included in the aforementioned studies were limited and subgroup analysis for CRC was not conducted [<xref ref-type="bibr" rid="pone.0163523.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0163523.ref049">49</xref>, <xref ref-type="bibr" rid="pone.0163523.ref050">50</xref>]. In the present study, we collected data from 13 studies involving a total of 8,601 patients and combined HRs and 95% CIs in both the random-effects model and fixed-effects model. Furthermore, various end-points for cancer patients including OS, DFS, RFS, CSS and TTR were analyzed in our study. Therefore, our meta-analysis involving patients with CRC is more comprehensive. Interestingly, in the present meta-analysis, we found that PLR was a significant prognostic marker for OS in CRC and colon cancer, but not in rectal cancer. This phenomenon may be due to the fact that different genetic features exist during colon and rectal carcinogenesis [<xref ref-type="bibr" rid="pone.0163523.ref051">51</xref>], and TP53 pathway is activated more frequently in rectal cancer than colon cancer. The activation of platelet-derived growth factor receptor alpha pathway is accompanied by the suppression of p53[<xref ref-type="bibr" rid="pone.0163523.ref052">52</xref>–<xref ref-type="bibr" rid="pone.0163523.ref054">54</xref>], which implies that the elevation of platelet counts may not be significant in rectal cancer carcinogenesis and could even be a protective factor in rectal cancer. Therefore, the increased PLR value was not found to be associated with OS in patients with rectal cancer, as suggested by our results.</p>
<p>Our study did however involve several limitations. Firstly, significant heterogeneity was observed among the included studies. Although we selected primary studies employing uniform inclusion and exclusion criteria, heterogeneity still existed between them. The heterogeneity was possibly due to the various patient ethnicities, different tumor stages, and various treatment methods used in the primary studies. Secondly, publication bias is inevitable in studies; articles with positive results are likely to be published, articles with negative results may not be published. Thus, the combined HR may have been overestimated. Thirdly, the primary studies that reported RFS, CSS, and TTR analysis were limited, so the results concerning RFS, CSS, and TTR should be treated with caution. Therefore, further well-designed and large-scale cohort studies are warranted to confirm the prognostic role of PLR in CRC.</p>
<p>In conclusion, our meta-analysis showed that high PLR was an effective and significant biomarker for poor OS, DFS, and RFS in patients with CRC, however; it did not demonstrate an association with CSS or TTR. Considering the limitations in our study, well-designed, large cohort studies are required to verify our results.</p>
</sec>
<sec id="sec014">
<title>Supporting Information</title>
<supplementary-material id="pone.0163523.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.s001" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<title/>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0163523.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.s002" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>Certificate of English editing from Editage.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0163523.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0163523.s003" xlink:type="simple">
<label>S2 File</label>
<caption>
<title>STATA program codes.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>This work was supported by a grant from the Clinical Features Research of Capital (No. Z141107002514160). We thank Editage (<ext-link ext-link-type="uri" xlink:href="http://www.editage.com/" xlink:type="simple">www.editage.com</ext-link>) for their English language editing service.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0163523.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weitz</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Koch</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Debus</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hohler</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Galle</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Buchler</surname> <given-names>MW</given-names></name>. <article-title>Colorectal cancer</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>365</volume>(<issue>9454</issue>):<fpage>153</fpage>–<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/s0140-6736(05)17706-x" xlink:type="simple">10.1016/s0140-6736(05)17706-x</ext-link></comment> <object-id pub-id-type="pmid">WOS:000226170700031</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siegel</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>. <article-title>Cancer statistics, 2016</article-title>. <source>CA: a cancer journal for clinicians</source>. <year>2016</year>;<volume>66</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>30</lpage>. Epub 2016/01/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3322/caac.21332" xlink:type="simple">10.3322/caac.21332</ext-link></comment> <object-id pub-id-type="pmid">26742998</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wolpin</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Mayer</surname> <given-names>RJ</given-names></name>. <article-title>Systemic treatment of colorectal cancer</article-title>. <source>Gastroenterology</source>. <year>2008</year>;<volume>134</volume>(<issue>5</issue>):<fpage>1296</fpage>–<lpage>310</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.gastro.2008.02.098" xlink:type="simple">10.1053/j.gastro.2008.02.098</ext-link></comment> <object-id pub-id-type="pmid">WOS:000255676700009</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McArdle</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Hole</surname> <given-names>DJ</given-names></name>. <article-title>Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation</article-title>. <source>Br J Cancer</source>. <year>2002</year>;<volume>86</volume>(<issue>3</issue>):<fpage>331</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj/bjc/6600120" xlink:type="simple">10.1038/sj/bjc/6600120</ext-link></comment> <object-id pub-id-type="pmid">WOS:000174449300004</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Coussens</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Werb</surname> <given-names>Z</given-names></name>. <article-title>Inflammation and cancer</article-title>. <source>Nature</source>. <year>2002</year>;<volume>420</volume>(<issue>6917</issue>):<fpage>860</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature01322" xlink:type="simple">10.1038/nature01322</ext-link></comment> <object-id pub-id-type="pmid">WOS:000179897300067</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grivennikov</surname> <given-names>SI</given-names></name>, <name name-style="western"><surname>Greten</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Karin</surname> <given-names>M</given-names></name>. <article-title>Immunity, Inflammation, and</article-title> <source>Cancer. Cell</source>. <year>2010</year>;<volume>140</volume>(<issue>6</issue>):<fpage>883</fpage>–<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2010.01.025" xlink:type="simple">10.1016/j.cell.2010.01.025</ext-link></comment> <object-id pub-id-type="pmid">WOS:000275746600012</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hanahan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Weinberg</surname> <given-names>RA</given-names></name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>;<volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>–<lpage>74</lpage>. Epub 2011/03/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2011.02.013" xlink:type="simple">10.1016/j.cell.2011.02.013</ext-link></comment> <object-id pub-id-type="pmid">21376230</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gunduz</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mutlu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tural</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Yildiz</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Uysal</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Coskun</surname> <given-names>HS</given-names></name>, <etal>et al</etal>. <article-title>Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer</article-title>. <source>Asia-Pacific journal of clinical oncology</source>. <year>2015</year>;<volume>11</volume>(<issue>4</issue>):<fpage>288</fpage>–<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/ajco.12358" xlink:type="simple">10.1111/ajco.12358</ext-link></comment> <object-id pub-id-type="pmid">WOS:000363678000008</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cetin</surname> <given-names>EHO</given-names></name>, <name name-style="western"><surname>Cetin</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Aras</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Topaloglu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Temizhan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kisacik</surname> <given-names>HL</given-names></name>, <etal>et al</etal>. <article-title>Platelet to Lymphocyte Ratio as a Prognostic Marker of In-Hospital and Long-Term Major Adverse Cardiovascular Events in ST-Segment Elevation Myocardial Infarction</article-title>. <source>Angiology</source>. <year>2016</year>;<volume>67</volume>(<issue>4</issue>):<fpage>336</fpage>–<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/0003319715591751" xlink:type="simple">10.1177/0003319715591751</ext-link></comment> <object-id pub-id-type="pmid">WOS:000371305600007</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>WY</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>LR</given-names></name>, <name name-style="western"><surname>Fang</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>YQ</given-names></name>, <name name-style="western"><surname>Braddock</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Platelet-to-Lymphocyte Ratio A Novel Prognostic Factor for Prediction of 90-day Outcomes in Critically Ill Patients With Diabetic Ketoacidosis</article-title>. <source>Medicine</source>. <year>2016</year>;<volume>95</volume>(<issue>4</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/md.0000000000002596" xlink:type="simple">10.1097/md.0000000000002596</ext-link></comment> <object-id pub-id-type="pmid">WOS:000370535400001</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Ace</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>McNamara</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Al-Mubarak</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Vera-Badillo</surname> <given-names>FE</given-names></name>, <name name-style="western"><surname>Hermanns</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis</article-title>. <source>Cancer epidemiology, biomarkers &amp; prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</source>. <year>2014</year>;<volume>23</volume>(<issue>7</issue>):<fpage>1204</fpage>–<lpage>12</lpage>. Epub 2014/05/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1055-9965.epi-14-0146" xlink:type="simple">10.1158/1055-9965.epi-14-0146</ext-link></comment> <object-id pub-id-type="pmid">24793958</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>McNamara</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Seruga</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Vera-Badillo</surname> <given-names>FE</given-names></name>, <name name-style="western"><surname>Aneja</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ocana</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis</article-title>. <source>Journal of the National Cancer Institute</source>. <year>2014</year>;<volume>106</volume>(<issue>6</issue>):<fpage>dju124</fpage>. Epub 2014/05/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/dju124" xlink:type="simple">10.1093/jnci/dju124</ext-link></comment> <object-id pub-id-type="pmid">24875653</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sierko</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Wojtukiewicz</surname> <given-names>MZ</given-names></name>. <article-title>Platelets and angiogenesis in malignancy</article-title>. <source>Seminars in thrombosis and hemostasis</source>. <year>2004</year>;<volume>30</volume>(<issue>1</issue>):<fpage>95</fpage>–<lpage>108</lpage>. Epub 2004/03/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-2004-822974" xlink:type="simple">10.1055/s-2004-822974</ext-link></comment> <object-id pub-id-type="pmid">15034801</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Suzuki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Aiura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ueda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kitajima</surname> <given-names>M</given-names></name>. <article-title>The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents</article-title>. <source>Pancreas</source>. <year>2004</year>;<volume>29</volume>(<issue>2</issue>):<fpage>132</fpage>–<lpage>40</lpage>. Epub 2004/07/17. <object-id pub-id-type="pmid">15257105</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shankaran</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Ikeda</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bruce</surname> <given-names>AT</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Swanson</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Old</surname> <given-names>LJ</given-names></name>, <etal>et al</etal>. <article-title>IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity</article-title>. <source>Nature</source>. <year>2001</year>;<volume>410</volume>(<issue>6832</issue>):<fpage>1107</fpage>–<lpage>11</lpage>. Epub 2001/04/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/35074122" xlink:type="simple">10.1038/35074122</ext-link></comment> <object-id pub-id-type="pmid">11323675</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mantovani</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Allavena</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sica</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Balkwill</surname> <given-names>F</given-names></name>. <article-title>Cancer-related inflammation</article-title>. <source>Nature</source>. <year>2008</year>;<volume>454</volume>(<issue>7203</issue>):<fpage>436</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature07205" xlink:type="simple">10.1038/nature07205</ext-link></comment> <object-id pub-id-type="pmid">WOS:000257860300038</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gunaldi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Goksu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Erdem</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gunduz</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Okuturlar</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tiken</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study</article-title>. <source>International journal of clinical and experimental medicine</source>. <year>2015</year>;<volume>8</volume>(<issue>4</issue>):<fpage>5937</fpage>–<lpage>42</lpage>. <object-id pub-id-type="pmid">WOS:000358377700140</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miyazaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yamasaki</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Tsuchiya</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Matsumoto</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kunizaki</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Taniguchi</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer</article-title>. <source>European Journal of Cardio-thoracic Surgery</source>. <year>2015</year>;<volume>47</volume>(<issue>4</issue>):<fpage>e140</fpage>–<lpage>e5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ejcts/ezu514" xlink:type="simple">10.1093/ejcts/ezu514</ext-link></comment> <object-id pub-id-type="pmid">25548132</object-id></mixed-citation></ref>
<ref id="pone.0163523.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Azab</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Radbel</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Bhatt</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Vonfrolio</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients</article-title>. <source>Med Oncol</source>. <year>2013</year>;<volume>30</volume>(<issue>1</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12032-012-0432-4" xlink:type="simple">10.1007/s12032-012-0432-4</ext-link></comment> <object-id pub-id-type="pmid">WOS:000316800800110</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kinoshita</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Onoda</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Imai</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Iwaku</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Oishi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fushiya</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma</article-title>. <source>Br J Cancer</source>. <year>2012</year>;<volume>107</volume>(<issue>6</issue>):<fpage>988</fpage>–<lpage>93</lpage>. Epub 2012/08/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/bjc.2012.354" xlink:type="simple">10.1038/bjc.2012.354</ext-link></comment> <object-id pub-id-type="pmid">22878374</object-id>; PubMed Central PMCID: PMCPmc3464773.</mixed-citation></ref>
<ref id="pone.0163523.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carruthers</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Tho</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kakumanu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>McCartney</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>McDonald</surname> <given-names>AC</given-names></name>. <article-title>Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer</article-title>. <source>Colorectal Disease</source>. <year>2012</year>;<volume>14</volume>(<issue>10</issue>):<fpage>E701</fpage>–<lpage>E7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1463-1318.2012.03147.x" xlink:type="simple">10.1111/j.1463-1318.2012.03147.x</ext-link></comment> <object-id pub-id-type="pmid">WOS:000308636300009</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Son</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>DY</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>BC</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SY</given-names></name>, <etal>et al</etal>. <article-title>Preoperative Plasma Hyperfibrinogenemia is Predictive of Poor Prognosis in Patients with Nonmetastatic Colon Cancer</article-title>. <source>Ann Surg Oncol</source>. <year>2013</year>;<volume>20</volume>(<issue>9</issue>):<fpage>2908</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1245/s10434-013-2968-8" xlink:type="simple">10.1245/s10434-013-2968-8</ext-link></comment> <object-id pub-id-type="pmid">WOS:000322663800017</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baranyai</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Krzystanek</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Josa</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Dede</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Agoston</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Szasz</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer</article-title>. <source>Thrombosis and haemostasis</source>. <year>2014</year>;<volume>111</volume>(<issue>3</issue>):<fpage>483</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1160/th13-08-0632" xlink:type="simple">10.1160/th13-08-0632</ext-link></comment> <object-id pub-id-type="pmid">WOS:000332355700013</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neofytou</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Smyth</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Giakoustidis</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>AZ</given-names></name>, <name name-style="western"><surname>Cunningham</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Mudan</surname> <given-names>S</given-names></name>. <article-title>Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor</article-title>. <source>Med Oncol</source>. <year>2014</year>;<volume>31</volume>(<issue>10</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12032-014-0239-6" xlink:type="simple">10.1007/s12032-014-0239-6</ext-link></comment> <object-id pub-id-type="pmid">WOS:000342079600053</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Szkandera</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pichler</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Absenger</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Stotz</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Arminger</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Weissmueller</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients</article-title>. <source>American journal of surgery</source>. <year>2014</year>;<volume>208</volume>(<issue>2</issue>):<fpage>210</fpage>–<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjsurg.2013.10.030" xlink:type="simple">10.1016/j.amjsurg.2013.10.030</ext-link></comment> <object-id pub-id-type="pmid">WOS:000341149400009</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ying</surname> <given-names>HQ</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>QW</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Pan</surname> <given-names>YQ</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>HL</given-names></name>, <etal>et al</etal>. <article-title>The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients</article-title>. <source>Med Oncol</source>. <year>2014</year>;<volume>31</volume>(<issue>12</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12032-014-0305-0" xlink:type="simple">10.1007/s12032-014-0305-0</ext-link></comment> <object-id pub-id-type="pmid">WOS:000344531800022</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choi</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Cleghorn</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Jackson</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Okrainec</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Quereshy</surname> <given-names>FA</given-names></name>. <article-title>Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer</article-title>. <source>Ann Surg Oncol</source>. <year>2015</year>;<volume>22</volume>:<fpage>S603</fpage>–<lpage>S13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1245/s10434-015-4571-7" xlink:type="simple">10.1245/s10434-015-4571-7</ext-link></comment> <object-id pub-id-type="pmid">WOS:000367288100045</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cochran</surname> <given-names>WG</given-names></name>. <article-title>The combination of estimates from different experiments</article-title>. <source>Biometrics</source>. <year>1954</year>;<volume>10</volume>(<issue>1</issue>):<fpage>101</fpage>–<lpage>29</lpage>.</mixed-citation></ref>
<ref id="pone.0163523.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JPT</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>Br Med J</source>. <year>2003</year>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.327.7414.557" xlink:type="simple">10.1136/bmj.327.7414.557</ext-link></comment> <object-id pub-id-type="pmid">WOS:000185283700028</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Controlled clinical trials</source>. <year>1986</year>;<volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>88</lpage>. Epub 1986/09/01. <object-id pub-id-type="pmid">3802833</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mantel</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Haenszel</surname> <given-names>W</given-names></name>. <article-title>Statistical aspects of the analysis of data from retrospective studies</article-title>. <source>Journal of the National Cancer Institute</source>. <year>1959</year>;<volume>22</volume>(<issue>4</issue>):<fpage>719</fpage>–<lpage>48</lpage>. <object-id pub-id-type="pmid">13655060</object-id></mixed-citation></ref>
<ref id="pone.0163523.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>101</lpage>. Epub 1994/12/01. <object-id pub-id-type="pmid">7786990</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ (Clinical research ed)</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>34</lpage>. Epub 1997/10/06. <object-id pub-id-type="pmid">9310563</object-id>; PubMed Central PMCID: PMCPmc2127453.</mixed-citation></ref>
<ref id="pone.0163523.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mori</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Toiyama</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Saigusa</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fujikawa</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hiro</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kobayashi</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery</article-title>. <source>Digestive Diseases and Sciences</source>. <year>2015</year>;<volume>60</volume>(<issue>8</issue>):<fpage>2477</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10620-015-3648-2" xlink:type="simple">10.1007/s10620-015-3648-2</ext-link></comment> <object-id pub-id-type="pmid">WOS:000359998000038</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ozawa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ishihara</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nishikawa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kiyomatsu</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer</article-title>. <source>International Journal of Colorectal Disease</source>. <year>2015</year>;<volume>30</volume>(<issue>9</issue>):<fpage>1165</fpage>–<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00384-015-2276-9" xlink:type="simple">10.1007/s00384-015-2276-9</ext-link></comment> <object-id pub-id-type="pmid">WOS:000360542000003</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Toiyama</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Inoue</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kawamura</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kawamoto</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Okugawa</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hiro</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Elevated Platelet Count as Predictor of Recurrence in Rectal Cancer Patients Undergoing Preoperative Chemoradiotherapy Followed by Surgery</article-title>. <source>International surgery</source>. <year>2015</year>;<volume>100</volume>(<issue>2</issue>):<fpage>199</fpage>–<lpage>207</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.9738/intsurg-d-13-00178.1" xlink:type="simple">10.9738/intsurg-d-13-00178.1</ext-link></comment> <object-id pub-id-type="pmid">WOS:000349957000003</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection</article-title>. <source>International journal of cancer Journal international du cancer</source>. <year>2016</year>. Epub 2016/03/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.30071" xlink:type="simple">10.1002/ijc.30071</ext-link></comment> <object-id pub-id-type="pmid">26933932</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>ZM</given-names></name>, <name name-style="western"><surname>Peng</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>CZ</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>J</given-names></name>. <article-title>Colon cancer with unresectable synchronous metastases: the AAAP scoring system for predicting the outcome after primary tumour resection</article-title>. <source>Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland</source>. <year>2016</year>;<volume>18</volume>(<issue>3</issue>):<fpage>255</fpage>–<lpage>63</lpage>. Epub 2015/09/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/codi.13123" xlink:type="simple">10.1111/codi.13123</ext-link></comment> <object-id pub-id-type="pmid">26400111</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zou</surname> <given-names>ZY</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>HL</given-names></name>, <name name-style="western"><surname>Ning</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>XH</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>R</given-names></name>. <article-title>Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer</article-title>. <source>Oncol Lett</source>. <year>2016</year>;<volume>11</volume>(<issue>3</issue>):<fpage>2241</fpage>–<lpage>8</lpage>. Epub 2016/03/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/ol.2016.4216" xlink:type="simple">10.3892/ol.2016.4216</ext-link></comment> <object-id pub-id-type="pmid">26998156</object-id>; PubMed Central PMCID: PMCPmc4774601.</mixed-citation></ref>
<ref id="pone.0163523.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klampfer</surname> <given-names>L</given-names></name>. <article-title>Cytokines, Inflammation and Colon Cancer</article-title>. <source>Current Cancer Drug Targets</source>. <year>2011</year>;<volume>11</volume>(<issue>4</issue>):<fpage>451</fpage>–<lpage>64</lpage>. <object-id pub-id-type="pmid">WOS:000290610400008</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kraus</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Arber</surname> <given-names>N</given-names></name>. <article-title>Inflammation and colorectal cancer</article-title>. <source>Current Opinion in Pharmacology</source>. <year>2009</year>;<volume>9</volume>(<issue>4</issue>):<fpage>405</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.coph.2009.06.006" xlink:type="simple">10.1016/j.coph.2009.06.006</ext-link></comment> <object-id pub-id-type="pmid">WOS:000269811600008</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sierko</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Wojtukiewicz</surname> <given-names>MZ</given-names></name>. <article-title>Inhibition of platelet function: does it offer a chance of better cancer progression control?</article-title> <source>Seminars in thrombosis and hemostasis</source>. <year>2007</year>;<volume>33</volume>(<issue>7</issue>):<fpage>712</fpage>–<lpage>21</lpage>. Epub 2007/11/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-2007-991540" xlink:type="simple">10.1055/s-2007-991540</ext-link></comment> <object-id pub-id-type="pmid">18000800</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Labelle</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Begum</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Hynes</surname> <given-names>RO</given-names></name>. <article-title>Platelets guide the formation of early metastatic niches</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>(<issue>30</issue>):<fpage>E3053</fpage>–<lpage>E61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1411082111" xlink:type="simple">10.1073/pnas.1411082111</ext-link></comment> <object-id pub-id-type="pmid">WOS:000339500200006</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenberg</surname> <given-names>SA</given-names></name>. <article-title>Progress in human tumour immunology and immunotherapy</article-title>. <source>Nature</source>. <year>2001</year>;<volume>411</volume>(<issue>6835</issue>):<fpage>380</fpage>–<lpage>4</lpage>. Epub 2001/05/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/35077246" xlink:type="simple">10.1038/35077246</ext-link></comment> <object-id pub-id-type="pmid">11357146</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>JX</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>HZ</given-names></name>. <article-title>Elevation of Platelet Count in Patients with Colorectal Cancer Predicts Tendency to Metastases and Poor Prognosis</article-title>. <source>Hepato-gastroenterology</source>. <year>2012</year>;<volume>59</volume>(<issue>118</issue>):<fpage>1687</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5754/hge12277" xlink:type="simple">10.5754/hge12277</ext-link></comment> <object-id pub-id-type="pmid">WOS:000309692100005</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monreal</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fernandez-Llamazares</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pinol</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Julian</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Broggi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Escola</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Platelet count and survival in patients with colorectal cancer—a preliminary study</article-title>. <source>Thrombosis and haemostasis</source>. <year>1998</year>;<volume>79</volume>(<issue>5</issue>):<fpage>916</fpage>–<lpage>8</lpage>. Epub 1998/06/03. <object-id pub-id-type="pmid">9609220</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huh</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>HR</given-names></name>. <article-title>Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer</article-title>. <source>Archives of Surgery</source>. <year>2012</year>;<volume>147</volume>(<issue>4</issue>):<fpage>366</fpage>–<lpage>71</lpage>. <object-id pub-id-type="pmid">WOS:000302904600017</object-id>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/archsurg.2012.35" xlink:type="simple">10.1001/archsurg.2012.35</ext-link></comment></mixed-citation></ref>
<ref id="pone.0163523.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qiang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Wen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis</article-title>. <source>OncoTargets and therapy</source>. <year>2016</year>;<volume>9</volume>:<fpage>869</fpage>–<lpage>76</lpage>. Epub 2016/03/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/ott.s96804" xlink:type="simple">10.2147/ott.s96804</ext-link></comment> <object-id pub-id-type="pmid">26955285</object-id>; PubMed Central PMCID: PMCPmc4768894.</mixed-citation></ref>
<ref id="pone.0163523.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nishijima</surname> <given-names>TF</given-names></name>, <name name-style="western"><surname>Muss</surname> <given-names>HB</given-names></name>, <name name-style="western"><surname>Shachar</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Tamura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takamatsu</surname> <given-names>Y</given-names></name>. <article-title>Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis</article-title>. <source>Cancer Treat Rev</source>. <year>2015</year>;<volume>41</volume>(<issue>10</issue>):<fpage>971</fpage>–<lpage>8</lpage>. Epub 2015/10/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ctrv.2015.10.003" xlink:type="simple">10.1016/j.ctrv.2015.10.003</ext-link></comment> <object-id pub-id-type="pmid">26481060</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>YP</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>ZB</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Qiu</surname> <given-names>TZ</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Prognostic Value of PLR in Various Cancers: A Meta-Analysis</article-title>. <source>PloS one</source>. <year>2014</year>;<volume>9</volume>(<issue>6</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0101119" xlink:type="simple">10.1371/journal.pone.0101119</ext-link></comment> <object-id pub-id-type="pmid">WOS:000338280800110</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Frattini</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Balestra</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Suardi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Oggionni</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Alberici</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Radice</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Different genetic features associated with colon and rectal carcinogenesis</article-title>. <source>Clin Cancer Res</source>. <year>2004</year>;<volume>10</volume>(<issue>12</issue>):<fpage>4015</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.ccr-04-0031" xlink:type="simple">10.1158/1078-0432.ccr-04-0031</ext-link></comment> <object-id pub-id-type="pmid">WOS:000222249100012</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lei</surname> <given-names>HT</given-names></name>, <name name-style="western"><surname>Velez</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Kazlauskas</surname> <given-names>A</given-names></name>. <article-title>Pathological Signaling via Platelet-Derived Growth Factor Receptor alpha Involves Chronic Activation of Akt and Suppression of p53</article-title>. <source>Molecular and cellular biology</source>. <year>2011</year>;<volume>31</volume>(<issue>9</issue>):<fpage>1788</fpage>–<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/mcb.01321-10" xlink:type="simple">10.1128/mcb.01321-10</ext-link></comment> <object-id pub-id-type="pmid">WOS:000289617300001</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ko</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Jung</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Seo</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>YR</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>HA</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>SJ</given-names></name>, <etal>et al</etal>. <article-title>Platelet-activating factor-induced NF-kappa B activation enhances VEGF expression through a decrease in p53 activity</article-title>. <source>FEBS letters</source>. <year>2006</year>;<volume>580</volume>(<issue>13</issue>):<fpage>3006</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.febslet.2006.04.042" xlink:type="simple">10.1016/j.febslet.2006.04.042</ext-link></comment> <object-id pub-id-type="pmid">WOS:000238107400003</object-id>.</mixed-citation></ref>
<ref id="pone.0163523.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>HE</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kasza</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Palmer</surname> <given-names>KC</given-names></name>, <etal>et al</etal>. <article-title>Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>1997</year>;<volume>39</volume>(<issue>3</issue>):<fpage>731</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/s0360-3016(97)00358-1" xlink:type="simple">10.1016/s0360-3016(97)00358-1</ext-link></comment> <object-id pub-id-type="pmid">WOS:A1997YA91700029</object-id>.</mixed-citation></ref>
</ref-list>
</back>
</article>